Filtros de búsqueda

Lista de obras de Ludwig Kappos

10 years of interferon beta-1b (Beta feron therapy

artículo científico publicado en 2005

2015 Multiple Sclerosis Experts Summit

artículo científico publicado en 2015

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

artículo científico publicado en 2009

3D GRASE arterial spin labelling reveals an inverse correlation of cortical perfusion with the white matter lesion volume in MS.

artículo científico publicado en 2012

A comparative analysis of Patient-Reported Expanded Disability Status Scale tools

artículo científico publicado en 2015

A comparison of brain magnetic resonance imaging lesions in multiple sclerosis by race with reference to disability progression

scholarly article by Yuri Nakamura et al published 5 September 2018 in Journal of Neuroinflammation

A confusing patient's history: small or large vessel vasculitis?

artículo científico publicado en 2009

A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients

artículo científico publicado en 2014

A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-up

artículo científico publicado en 2015

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

artículo científico publicado en 2010

Abnormal connectivity of the sensorimotor network in patients with MS: A multicenter fMRI study

Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis

scientific article published on 17 August 2009

Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients

artículo científico publicado en 2010

Altered functional adaptation to attention and working memory tasks with increasing complexity in relapsing‐remitting multiple sclerosis patients ⬇️

artículo científico publicado el 12 de noviembre de 2010

Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects.

artículo científico publicado en 2012

Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future?

artículo científico publicado en 2004

Analysis of impairment related functional architecture in MS patients during performance of different attention tasks

artículo científico publicado en 2003

Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype

artículo científico publicado en 2015

Antigen Extraction and B Cell Activation Enable Identification of Rare Membrane Antigen Specific Human B Cells

Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF.

artículo científico publicado en 2007

Assessing response to interferon-β in a multicenter dataset of patients with MS.

artículo científico publicado en 2016

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study

artículo científico publicado en 2013

Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years

artículo científico publicado en 2019

Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b

artículo científico publicado en 2015

Association of brain volume loss and long-term disability outcomes in patients with multiple sclerosis treated with teriflunomide

artículo científico publicado en 2019

Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial

artículo científico publicado en 2014

Atorvastatin added to interferon beta for relapsing multiple sclerosis: 12-month treatment extension of the randomized multicenter SWABIMS trial

artículo científico publicado en 2014

Atorvastatin added to interferon β for relapsing multiple sclerosis: a randomized controlled trial

artículo científico publicado en 2012

Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosis

artículo científico publicado en 2003

Automatic Spinal Cord Gray Matter Quantification: A Novel Approach

artículo científico publicado en 2019

Balance control in multiple sclerosis: correlations of trunk sway during stance and gait tests with disease severity

artículo científico publicado en 2012

Biplanar MRI for the assessment of the spinal cord in multiple sclerosis

artículo científico publicado en 2012

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response

article by Jens Kuhle et al published 5 March 2019 in Neurology

Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study.

artículo científico publicado en 2018

Case-Based fMRI Analysis after Cognitive Rehabilitation in MS: A Novel Approach

artículo científico publicado en 2015

Cerebellar abnormalities contribute to disability including cognitive impairment in multiple sclerosis

artículo científico publicado en 2014

Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis

artículo científico publicado en 2014

Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes

artículo científico publicado en 2015

Clinical effects of natalizumab on multiple sclerosis appear early in treatment course

artículo científico publicado en 2013

Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study

artículo científico publicado en 2013

Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri® Observational Program (TOP)

scientific article published on 14 May 2020

Clinical trials in multiple sclerosis

artículo científico publicado en 2014

Cocapture of cognate and bystander antigens can activate autoreactive B cells

artículo científico publicado en 2017

Cognitive rehabilitation of working memory in juvenile multiple sclerosis-effects on cognitive functioning, functional MRI and network related connectivity

artículo científico publicado en 2015

Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML

artículo científico publicado en 2020

Combined visual and motor evoked potentials predict multiple sclerosis disability after 20 years

artículo científico publicado en 2014

Comparative efficacy of switching to natalizumab in active multiple sclerosis

artículo científico publicado en 2015

Comparison between balanced steady-state free precession and standard spoiled gradient echo magnetization transfer ratio imaging in multiple sclerosis: methodical and clinical considerations

artículo científico publicado en 2014

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

artículo científico publicado en 2011

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial

artículo científico publicado en 2011

Competing interests in multiple sclerosis research.

artículo científico publicado en 2003

Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis

artículo científico publicado en 2017

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials

artículo científico publicado en 2020

Contribution of cortical and white matter lesions to cognitive impairment in multiple sclerosis.

artículo científico publicado en 2013

Copeptin: a novel, independent prognostic marker in patients with ischemic stroke

artículo científico publicado en 2009

Correction: Prognostic implications of a carefully performed neurological assessment in patients with a first event suggestive of multiple sclerosis.

artículo científico publicado en 2011

Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis

artículo científico publicado en 2015

DACLIZUMAB HYP VS IM INTERFERON BETA-1A IN MS: NEDA RESULTS FROM DECIDE

artículo científico publicado en 2016

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

artículo científico publicado en 2015

Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS.

artículo científico publicado en 2016

Defining the clinical course of multiple sclerosis: the 2013 revisions

artículo científico publicado en 2014

Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience

artículo científico publicado en 2015

Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM.

artículo científico publicado en 2016

Detection of cerebrospinal fluid leaks by intrathecal contrast-enhanced magnetic resonance myelography.

artículo científico publicado en 2013

Determinants of iron accumulation in deep grey matter of multiple sclerosis patients

artículo científico publicado en 2014

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

artículo científico publicado en 2017

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

artículo científico publicado en 2005

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

artículo científico publicado en 2011

Dimethyl fumarate for multiple sclerosis.

artículo científico publicado en 2010

Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis

artículo científico publicado en 2017

Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate

artículo científico publicado en 2020

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

artículo científico publicado en 2018

Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study

artículo científico publicado en 2011

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.

artículo científico publicado en 2018

Effect of drugs in secondary disease progression in patients with multiple sclerosis

artículo científico publicado en 2004

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

artículo científico publicado en 2007

Effect of immunomodulatory medication on regional gray matter loss in relapsing-remitting multiple sclerosis--a longitudinal MRI study

artículo científico publicado en 2010

Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial

artículo científico publicado en 2023

Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies

artículo científico

Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study

artículo científico publicado en 2014

Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis

artículo científico publicado en 2012

Efficacy and Safety of Fingolimod in an Unselected Patient Population

artículo científico publicado en 2016

Efficacy and safety of interferon beta-1b sc in older RRMS patients—a posthoc analysis of the BEYOND study

article

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

artículo científico publicado en 2008

Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes

artículo científico publicado en 2013

Endonasal surgery for contact point headaches: a 10-year longitudinal study

artículo científico publicado en 2003

Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP)

artículo científico publicado en 2016

Evaluation of a new approach for semi-automatic segmentation of the cerebellum in patients with multiple sclerosis

artículo científico publicado en 2012

Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial

Evidence for acute neurotoxicity after chemotherapy ⬇️

artículo científico publicado el 1 de diciembre de 2010

Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients

artículo científico publicado en 2015

Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process

artículo científico publicado en 2015

Extraocular blood flow and endothelin-1 plasma levels in patients with multiple sclerosis

artículo científico publicado en 2003

Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15.

artículo científico publicado en 2015

Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis

artículo científico publicado en 2015

Fingolimod effect on gray matter, thalamus, and white matter in patients with multiple sclerosis.

artículo científico publicado en 2018

Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directions

artículo científico

Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings

artículo científico publicado en 2014

First-dose effects of fingolimod: Pooled safety data from three phase 3 studies

artículo científico publicado en 2014

Five-years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension

artículo científico publicado en 2020

Fluid biomarker and electrophysiological outcome measures for progressive MS trials

artículo científico publicado en 2017

Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis

scientific journal article

Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene

artículo científico publicado en 2010

Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci

artículo científico publicado en 2011

Genomics and proteomics: role in the management of multiple sclerosis

artículo científico publicado en 2005

Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration

artículo científico publicado en 2013

Glutamate gene polymorphisms predict brain volumes in multiple sclerosis

artículo científico publicado en 2012

Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study

artículo científico publicado en 2017

Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability

article by Stefan D Roosendaal et al published 17 May 2011 in Multiple Sclerosis Journal

Health-related quality of life in multiple sclerosis: effects of natalizumab

artículo científico publicado en 2007

Histone deacetylase gene variants predict brain volume changes in multiple sclerosis

artículo científico publicado en 2012

Homing frequency of human T cells inferred from peripheral blood depletion kinetics after sphingosine-1-phosphate receptor blockade

artículo científico publicado en 2013

Images in clinical medicine. Dissociation of voluntary and emotional innervation after stroke

artículo científico publicado en 2010

Immune-mediated neuropathies: etiology and pathogenic relationship to aging processes

artículo científico publicado en 2003

Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS.

artículo científico publicado en 2015

Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis

artículo científico

Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study

artículo científico publicado en 2013

Improved characterization of visual evoked potentials in multiple sclerosis by topographic analysis

scientific article published on 02 October 2013

Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial

artículo científico publicado en 2016

Increased neurofilament light chain blood levels in neurodegenerative neurological diseases

artículo científico publicado en 2013

Individual Assessment of Brain Tissue Changes in MS and the Effect of Focal Lesions on Short-Term Focal Atrophy Development in MS: A Voxel-Guided Morphometry Study

artículo científico publicado en 2016

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune responsein multiple sclerosis after administration of an altered peptide ligand ina placebo-controlled, randomized phase II trial

article

Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis

artículo científico publicado en 2016

Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome

artículo científico publicado en 2013

Interferon-beta antibodies: implications for the treatment of MS.

artículo científico publicado en 2003

Interferons in multiple sclerosis

artículo científico publicado en 2005

Interleukin 17F level and interferon β response in patients with multiple sclerosis

artículo científico publicado en 2013

Label-fusion-segmentation and deformation-based shape analysis of deep gray matter in multiple sclerosis: the impact of thalamic subnuclei on disability

artículo científico publicado en 2014

Lack of association between antimyelin antibodies and progression to multiple sclerosis

artículo científico publicado en 2007

Laminar analysis of the cerebellar cortex shows widespread damage in early MS patients: A pilot study at 7T MRI

artículo científico publicado en 2020

Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials

artículo científico publicado en 2017

Learning ability correlates with brain atrophy and disability progression in RRMS

artículo científico publicado en 2018

Learning from nature: pregnancy changes the expression of inflammation-related genes in patients with multiple sclerosis

artículo científico publicado en 2010

Lesion-to-ventricle distance and other risk factors for the persistence of newly formed black holes in relapsing-remitting multiple sclerosis

artículo científico publicado en 2013

Letter Re: Retraction: Risedronate Therapy For Prevention Of Hip Fracture After Stroke In Elderly Women; Risedronate Therapy For Prevention Of Hip Fracture After Stroke In Elderly Women: Reply From The Authors

artículo científico publicado en 2017

Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study

artículo científico publicado en 2015

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

artículo científico publicado en 2009

Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study

artículo científico publicado en 2016

Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial

artículo científico publicado en 2015

Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial

artículo científico publicado en 2020

Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study★★

scientific article published on 24 May 2019

Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis

artículo científico publicado en 2015

Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study

artículo científico publicado en 2014

Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study

artículo científico publicado en 2016

Longitudinal gray matter changes in multiple sclerosis--differential scanner and overall disease-related effects

artículo científico publicado en 2011

MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice

artículo científico publicado en 2020

MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome

artículo científico publicado en 2009

MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines

artículo científico publicado en 2016

MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials

artículo científico

MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis

artículo científico publicado en 2015

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study

artículo científico publicado en 2014

Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results

artículo científico

Magnetic resonance imaging outcomes from a phase III trial of teriflunomide

artículo científico publicado en 2013

Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study

artículo científico publicado en 2009

Magnetization transfer ratio in lesions rather than normal-appearing brain relates to disability in patients with multiple sclerosis

artículo científico publicado en 2015

Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study

artículo científico publicado en 2014

Mannose-binding lectin deficiency is associated with smaller infarction size and favorable outcome in ischemic stroke patients

artículo científico publicado en 2011

Measuring and Validating the Levels of Brain-Derived Neurotrophic Factor in Human Serum.

artículo científico publicado en 2018

Mental health problems in children of somatically ill parents, e.g. multiple sclerosis.

artículo científico publicado en 2006

Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci

artículo científico publicado en 2009

MiR-126: a novel route for natalizumab action?

artículo científico publicado en 2014

Mitochondrial cytopathy with common MELAS mutation presenting as multiple system atrophy mimic

artículo científico publicado en 2016

Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data

artículo científico publicado en 2011

Molecular mechanism underlying the impact of vitamin D on disease activity of MS.

artículo científico publicado en 2014

Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice

artículo científico

Multicenter R2* mapping in the healthy brain

artículo científico publicado en 2014

Multiple sclerosis as a generalized CNS disease--comparative microarray analysis of normal appearing white matter and lesions in secondary progressive MS.

artículo científico publicado en 2004

Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life - A post hoc analysis of the TEMSO and TOWER studies

artículo científico publicado en 2016

Multivariate pattern classification of gray matter pathology in multiple sclerosis

artículo científico publicado en 2012

Natalizumab therapy for multiple sclerosis

artículo científico publicado en 2013

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

artículo científico publicado en 2007

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

artículo científico publicado en 2011

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting

artículo científico publicado en 2018

Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development

artículo científico publicado en 2016

Natalizumab: targeting alpha4-integrins in multiple sclerosis

artículo científico publicado en 2008

Neurofilament light levels are associated with long-term outcomes in multiple sclerosis

scientific article published on 04 November 2019

Neurofilaments as biomarkers in neurological disorders

article by Michael Khalil et al published 31 August 2018 in Nature Reviews Neurology

Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study

artículo científico publicado en 2016

Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report

artículo científico publicado en 2007

Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial

artículo científico publicado en 2011

No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.

artículo científico publicado en 2015

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.

artículo científico publicado en 2018

No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study

artículo científico publicado en 2016

Non-communicating syringomyelia: a feature of spinal cord involvement in multiple sclerosis

Nonconventional MRI and microstructural cerebral changes in multiple sclerosis.

artículo científico publicado en 2015

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis

Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis

artículo científico publicado en 2017

Ocrelizumab in relapsing and primary progressive multiple sclerosis: pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO

artículo científico publicado en 2020

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

artículo científico publicado en 2011

Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies

scientific article published on 28 January 2019

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

artículo científico publicado en 2016

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

artículo científico publicado en 2016

Oculopharyngeal muscular dystrophy - an under-diagnosed disorder?

artículo científico publicado en 2005

Ofatumumab versus Teriflunomide in Multiple Sclerosis

artículo científico publicado en 2020

On the origin of Neurostatus.

artículo científico publicado en 2015

Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis

artículo científico publicado en 2015

Optimizing brain MRI protocols in the follow-up of patients with multiple sclerosis T2-weighted MRI of the brain after the administration of gadopentetate dimeglumine

artículo científico publicado en 2005

Optimizing treatment initiation: Effects of a patient education program about fingolimod treatment on knowledge, self-efficacy and patient satisfaction

artículo científico publicado en 2015

Oral fingolimod (FTY720) for relapsing multiple sclerosis

artículo científico publicado en 2006

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

artículo científico publicado en 2016

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

artículo científico publicado en 2010

Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial

artículo científico publicado en 2014

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

artículo científico publicado en 2014

PARP-1 deregulation in multiple sclerosis

artículo científico publicado en 2019

PML risk and natalizumab: the elephant in the room

artículo científico publicado en 2017

PML with dimethyl fumarate-No convincing case against natalizumab

scientific article published on 22 August 2019

Pathway and network-based analysis of genome-wide association studies in multiple sclerosis

scientific article published on 13 March 2009

Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study

scientific article published on 12 January 2014

Performance of five research-domain automated WM lesion segmentation methods in a multi-center MS study.

artículo científico publicado en 2017

Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies

artículo científico publicado en 2007

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

artículo científico publicado en 2012

Placebo-controlled trial of oral laquinimod for multiple sclerosis

artículo científico publicado en 2012

Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage

artículo científico

Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions

artículo científico publicado en 2015

Power estimation for non-standardized multisite studies

artículo científico publicado en 2016

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis

artículo científico publicado en 2012

Predicting PML in natalizumab-treated patients: can we do better?

artículo científico publicado en 2013

Predictors of disease activity in 857 patients with MS treated with interferon beta-1b

artículo científico publicado en 2015

Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy

Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis

scientific article published on 24 January 2014

Preserved antigen-specific immune response in patients with multiple sclerosis responding to IFNβ-therapy

artículo científico publicado en 2013

Prognostic factors for long-term outcomes in relapsing-remitting multiple sclerosis

artículo científico publicado en 2016

Progression in disability and regional grey matter atrophy in relapsing–remitting multiple sclerosis

artículo científico publicado en 2013

Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: the DEFINE study

artículo científico publicado en 2013

Quantified CSF antibody reactivity against myelin in multiple sclerosis

artículo científico publicado en 2015

Quantifying progression of multiple sclerosis via classification of depth videos

Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations

artículo científico publicado en 2018

Randomized trial of oral teriflunomide for relapsing multiple sclerosis

artículo científico publicado en 2011

Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis

artículo científico publicado en 2015

Rapamycin attenuates the progression of tau pathology in P301S tau transgenic mice

artículo científico publicado en 2013

Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program

artículo científico publicado en 2020

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study

artículo científico publicado en 2012

Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies

artículo científico

Relation between functional brain imaging, cognitive impairment and cognitive rehabilitation in patients with multiple sclerosis

artículo científico publicado en 2007

Relevance of spinal cord abnormalities to clinical disability in multiple sclerosis: MR imaging findings in a large cohort of patients

artículo científico publicado en 2013

Reliability and acceptance of dreaMS, a software application for people with multiple sclerosis: a feasibility study

artículo científico publicado en 2022

Reply

Retraining attention in MS.

artículo científico publicado en 2006

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients

artículo científico publicado en 2017

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

artículo científico publicado en 2012

Réduction à long-terme du taux de poussées et de progression du handicap après 6 ans de traitement par ocrelizumab (OCR) chez des patients atteints de sclérose en plaques récurrente (SEP-R)

scientific article published on 01 September 2020

SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts

artículo científico publicado en 2017

Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study

artículo científico

Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial

artículo científico publicado en 2016

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

artículo científico publicado en 2014

Safety and tolerability profile of daclizumab in patients with relapsing-remitting multiple sclerosis: An integrated analysis of clinical studies

artículo científico publicado en 2016

Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis

artículo científico publicado en 2015

Screening for balance disorders in mildly affected multiple sclerosis patients

artículo científico publicado en 2011

Secondary progressive multiple sclerosis: current knowledge and future challenges

artículo científico publicado en 2006

Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis

artículo científico

Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis

article by Nelly Siller et al published 15 March 2018 in Multiple Sclerosis Journal

Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome

artículo científico publicado en 2014

Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome

artículo científico publicado en 2015

Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy

artículo científico publicado en 2016

Short-term and long-term safety and tolerability of interferon β-1b in multiple sclerosis

artículo científico publicado en 2013

Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis

artículo científico publicado en 2018

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

artículo científico publicado en 2013

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

artículo científico publicado en 2018

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis

scientific article published on 18 November 2020

Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions

artículo científico publicado en 2018

Sodium intake and multiple sclerosis activity and progression in BENEFIT.

artículo científico publicado en 2017

Spatiotemporal distribution of white matter lesions in relapsing-remitting and secondary progressive multiple sclerosis

artículo científico publicado en 2012

Spatiotemporal distribution pattern of white matter lesion volumes and their association with regional grey matter volume reductions in relapsing-remitting multiple sclerosis

artículo científico publicado en 2010

Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials

Subcortical brain segmentation of two dimensional T1-weighted data sets with FMRIB's Integrated Registration and Segmentation Tool (FIRST).

artículo científico publicado en 2014

Subcutaneous interferon β-1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study

artículo científico publicado en 2016

Survey of diagnostic and treatment practices for multiple sclerosis in Europe, part 2: progressive MS, paediatric MS, pregnancy and general management

artículo científico publicado en 2018

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS

artículo científico publicado en 2015

T-cell response against varicella-zoster virus in fingolimod-treated MS patients

artículo científico publicado en 2013

Teriflunomide for oral therapy in multiple sclerosis

artículo científico publicado en 2012

Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use.

artículo científico publicado en 2013

Teriflunomide reduces relapses with sequelae and relapses leading to hospitalizations: results from the TOWER study

artículo científico publicado en 2014

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.

artículo científico publicado en 2013

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial

artículo científico publicado en 2016

The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis

artículo científico publicado en 2020

The Janus face of CNS-directed autoimmune response: a therapeutic challenge

artículo científico publicado en 2002

The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options

artículo científico publicado en 2016

The current role of MRI in differentiating multiple sclerosis from its imaging mimics.

artículo científico publicado en 2018

The distribution of magnetic resonance imaging response to interferonβ–1b in multiple sclerosis

article

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

artículo científico publicado en 2015

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL

artículo científico publicado en 2009

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

artículo científico publicado en 2009

The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies.

artículo científico publicado en 2017

The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges

artículo científico publicado en 2020

The relationship between total and regional corpus callosum atrophy, cognitive impairment and fatigue in multiple sclerosis patients

artículo científico publicado en 2013

The role of cerebellar abnormalities in neuromyelitis optica--a comparison with multiple sclerosis and healthy controls

artículo científico publicado en 2014

The role of the cerebellum in multiple sclerosis-150 years after Charcot.

artículo científico publicado en 2018

Therapy-induced plasticity of cognitive functions in MS patients: insights from fMRI.

artículo científico publicado en 2006

Tolérance d’ocrelizumab (OCR) : analyse actualisée des données de tolérance des patients atteints de sclérose en plaques récurrente (SEP-R) et de sclérose en plaques primaire progressive (SEP-PP)

scientific article published on 01 September 2020

Transcriptional profiling of multiple sclerosis: towards improved diagnosis and treatment

artículo científico publicado en 2006

Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis

artículo científico publicado en 2017

Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge

artículo científico publicado en 2018

Usability and Acceptability of ASSESS MS: Assessment of Motor Dysfunction in Multiple Sclerosis Using Depth-Sensing Computer Vision.

artículo científico publicado en 2015

Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies

artículo científico publicado en 2012

Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management

artículo científico publicado en 2015

Vitamin D as an early predictor of multiple sclerosis activity and progression

artículo científico publicado en 2014

What is new in MS spasticity research? Poster session highlights

artículo científico publicado en 2015

White matter lesion filling improves the accuracy of cortical thickness measurements in multiple sclerosis patients: a longitudinal study

artículo científico publicado en 2014

White matter lesion location correlates with disability in relapsing multiple sclerosis

artículo científico publicado en 2020

Working memory training in patients with multiple sclerosis - comparison of two different training schedules.

artículo científico publicado en 2009

α4-integrin receptor desaturation and disease activity return after natalizumab cessation

artículo científico publicado en 2017

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda